

REFERENCIAS

- American Psychiatric Association (1997). Practice guidelines for the treatment of patients with schizophrenia. *American Journal of Psychiatry* 154, 1-49.
- Delay , J., Deniker, P. (1952). 38 cas de psychoses traitées par la cure prolongée et continué de 4560RP. *Comptes Rendus du 50 Congrès des Médecins Aliénistes et Neurologistes de Langue Francaise*, 503-513.
- Deniker P. From chlorpromazine to tardive dyskinesia (brief history of the neuroleptics). (1989). *Psychiatry Journal of the University of Ottawa*, 14, 253-259.
- Foussias, G., Remington, G. (2010). Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making. *Canadian Journal of Psychiatry*, 55, 117-125.
- Geddes, J., Freemantle, N., Harrison, P. et al. (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. *British Medical Journal*, 321, 1371-1376.
- Gilbert, P.L., Harris, M.J., McAdams, L.A. et al. (1995). Neuroleptic withdrawal in schizophrenia patients. A review of the literature. *Archives of General Psychiatry*, 52, 173-188.
- Haddad, P.M., Sharman, S.G. (2007). Adverse effects of atypical antipsychotic drugs: differential risk and clinical implications. *CNS Drugs*, 21, 911-936.
- Hill,S.K., Bishop, J.R., Palumbo, D., Sweeney, J.A. (2010). Effect of second-generation antipsychotics on cognition: current issues and future challenges. *Expert Reviews in Neurotherapy*, 10, 43-57.
- Ho, B.C., Andreasen, N.C., Ziebell, S., Pierson,R., Magnotta V. (2011). Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. *Archives of General Psychiatry*, 68, 128-137.
- Jauhar, S., Guloksuz, S., Andlauer, O., Lydall, G. et al. (2012). European Federation of Psychiatric Trainees' Research Group. Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence? *BMC Psychiatry*, 30, 12-27.
- Kane, J., Honifeld, G., Singer, J. et al. (1988). Clozapine for the treatment-resistant schizophrenia. *Archives of General Psychiatry*, 45, 789-796.
- Kaplin, H.I., Sadcock B.J. (eds) (1989). *Comprehensive Textbook of Psychiatry*, 5^a Ed., vol 2. (Baltimore, MD: Williams & Wiltkins) p. 1607.
- Lepping, P., Sambhi, R.S., Whittington, R., Lane, S., Poole, R. (2011). Clinical relevance of findings in trials of antipsychotics: systematic review. *British Journal of Psychiatry*, 198, 341-345.
- Leslie DL, Rosenheck R. (2012). Off-label use of antipsychotic medications in medicaid. *American Journal of Managed Care*, 18, e109-e1117.

López-Muñoz, F., Alamo, C., Cuenca, E., Shen, W.W., Clervoy, P., Rubio, G. (2005). History of the discovery and clinical introduction of chlorpromazine. *Annals of Clinical Psychiatry*, 17, 113-135.

Obermeier, M., Schennach-Wolff, R., Meyer, S., Möller, H.J., Riedel, M., Krause, D., Seemüller, F. (2011). Is the PANSS used correctly? a systematic review. *BMC Psychiatry*, 18, 113-116.

Saha, S., Chant, D., McGrath, J. (2007). A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? *Archives of General Psychiatry*, 64, 1123-1131.

Stip, E. (2002). Happy birthday neuroleptics! 50 years later: la folie du doute. *European Psychiatry*, 17, 115-119.

Tandon, R., Nasrallah, H.A., Keshavan, M.S. (2010). Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. *Schizophrenia Research*, 122, 1-23.

Thornley, B., Adams, C. (1998). Content and quality of 2000 controlled trials in schizophrenia over 50 years. *British Medical Journal*, 317, 1181-1184.

Turner, E.H., Knoopfmacher, D., Shapley, L. (2012). Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. *PLoS Medicine*, 9(3), e1001189.